A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.
Joel Raskin, Anita H Clayton, Susan G Kornstein...
https://pubmed.ncbi.nlm.nih.gov/41099447